Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Australia-based biopharmaceutical company Anadis has announced that the clinical protocol for its cancer-related mucositis program has been cleared by the Tel Aviv Souraski Medical Center's institutional review board and by the Israeli Ministry of Health.
Subscribe to our email newsletter
This clearance enables the initiation of the clinical trial addressing this significant target at the medical center within a month. The intended product, primarily for the oncology market, is expected to leverage a formulation of Anadis’s immune milk-derived anti LPS antibodies, growth factors and other bioactives combined and delivered using Anadis’s patented oral delivery technology.
Anadis anticipates a commercial product could reach the market within two-three years, due to the product’s safety profile.